UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD BIOFRONTERA INCORPORATED, BIOFRONTERA BIOSCIENCE GMBH, BIOFRONTERA PHARMA GMBH, **AND BIOFRONTERA AG Petitioners** v. DUSA PHARMACEUTICALS, INC. **Patent Owner** PATENT 10,357,567

DECLARATION OF HOWARD ROGERS, MD, PHD



Biofrontera Exhibit 1003 Biofrontera Inc. et al. v. DUSA Pharmaceuticals, Inc. IPR2022-00056

TABLE OF CONTENTS

I.	Educa	cation and Experience1				
II.	Comp	pensation3				
III.	Legal	Legal Considerations				
	A.	Anticipation				
	B.	Obviousness		5		
	C.	Claim Const	ruction	8		
IV.	Level	of Ordinary Skill in the Art				
V.	Task	Summary				
VI.	State of the Art14					
	A.	5-Aminolevulinic Acid (ALA) Photodynamic Therapy1				
	B.	Light Sources Utilized in ALA PDT1				
	C.	Treating Actinic Keratosis using PDT				
	D.	Occlusion with plastic wrap to minimize transepidermal water loss and enhance penetration of ALA was well known				
	E.	State of the Art Summary30				
VII.	The '567 Patent					
	A.	The '567 Patent Description and Claims				
	B.	'567 Patent A	Application (U.S. Patent Application No. 15/86	9,164)42		
VIII.				47		
IX.	Application of the Prior Art to the Challenged Claims48					
	A.	Ground 1: C	laims 1-4 and 6-10 Are Taught by Willey	49		
		1. Claim	1	50		
		2. Claim	1a	51		
		3. Claim	1b	52		
		4. Claim	1c	54		
		5. Claim	2	57		
		6. Claim	3	58		
		7. Claim	4	61		
		8. Claim	4a	61		



	9.	Claim 4b	61			
	10.	Claim 4c	62			
	11.	Claim 6 / Claim 7	62			
	12.	Claim 8	64			
	13.	Claim 8a	65			
	14.	Claim 8b	66			
	15.	Claim 8c	67			
	16.	Claim 8d	70			
	17.	Claim 9	70			
	18.	Claim 10	72			
B.		and 2 – Claim 3 Is Met by the Combination of Willey with				
	Ame	eluz				
	1.	Claim 3	74			
C.		Ground 3 – Claim 5 Is Met by the Combination of Willey with				
	2.	riou				
D.	_,	Claim 5				
D.	1.	and 4: Claims 1-9 Are Taught by Noven Pharma Claim 1				
	1. 2.	Claim 1a				
	2.3.	Claim 1b				
	3. 4.					
	4. 5.	Claim 1c Claim 2				
	5. 6.					
	0. 7.	Claim 4				
	7. 8.	Claim 4a				
	o. 9.	Claim 4b				
	9. 10.	Claim 4c				
	10. 11.					
		Claim 5				
	12.	Claim 6 / Claim 7				
	13.	Claim 8				
	14.	Claim 8a	106			



		15.	Claim 8b	108		
		16.	Claim 8c	109		
		17.	Claim 8d	110		
		18.	Claim 9	110		
	Е.	Ground 5 – Claim 3 Is Met by the Combination of Noven Pharma and Fauteck				
		3.	Claim 3	114		
	F.		Ground 6 – Claim 10 Is Met by the Combination of Noven Pharma with the BLU-U Operating Manual			
		2.	Claim 10	119		
X.	Clain	Claim Charts				
	A.	Ground 1: Claims 1-4 and 6-10 are taught by Willey1				
	B.	Ground 2: Claim 3 is met by the combination of Willey with Ameluz				
	C.	Ground 3: Claim 5 is met by the combination of Willey with Sotiriou				
	D.	Ground 4: Claims 1-9 are taught by Noven Pharma135				
	E.	Ground 5: Claim 3 is met by the combination of Noven Pharma with Fauteck				
	F.	Ground 6: Claim 10 is met by the combination of Noven Pharma with the BLU-U operating manual				
XI.	Addi	Additional Remarks152				



DECLARATION OF DR. HOWARD ROGERS

- 1. I, Howard Rogers, declare as follows:
- 2. My name is Howard Rogers. I am over the age of twenty-one (21) years, of sound mind, and capable of making the statements set forth in this Declaration. I am competent to testify about the matters set forth herein. All the facts and statements contained herein are within my personal knowledge and they are, in all things, true and correct.
- 3. I have been asked by Biofrontera Incorporated, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG (collectively, "Biofrontera") to submit this declaration in support of their challenge to the validity of all claims of U.S. Patent No. 10,357,567 ("the '567 patent").

I. Education and Experience

- 4. My *curriculum vita* is attached as Exhibit 1004.
- 5. I am a board-certified dermatologist and a fellowship-trained Mohs micrographic surgeon. I received a Bachelor of Science degree in Biology from Harvard University in 1989, where I graduated magna cum laude. My undergraduate thesis research focused on the immunological response of mast cells. I attended medical school at Washington University School of Medicine in St. Louis from 1989-1996. I graduated with honors, with both an M.D. and a Ph.D. My Ph.D. thesis involved seminal research into mechanisms of infectious immunity. At graduation,



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

